V Square Quantitative Management LLC Increases Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

V Square Quantitative Management LLC boosted its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 568.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 90,329 shares of the company’s stock after purchasing an additional 76,819 shares during the quarter. V Square Quantitative Management LLC’s holdings in Dr. Reddy’s Laboratories were worth $1,423,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in RDY. Farther Finance Advisors LLC increased its position in shares of Dr. Reddy’s Laboratories by 43.2% during the third quarter. Farther Finance Advisors LLC now owns 454 shares of the company’s stock worth $36,000 after purchasing an additional 137 shares in the last quarter. POM Investment Strategies LLC raised its stake in Dr. Reddy’s Laboratories by 400.0% in the fourth quarter. POM Investment Strategies LLC now owns 2,275 shares of the company’s stock valued at $36,000 after buying an additional 1,820 shares during the last quarter. Independence Bank of Kentucky boosted its holdings in Dr. Reddy’s Laboratories by 400.0% in the fourth quarter. Independence Bank of Kentucky now owns 2,775 shares of the company’s stock worth $44,000 after acquiring an additional 2,220 shares in the last quarter. Venturi Wealth Management LLC purchased a new stake in shares of Dr. Reddy’s Laboratories during the third quarter worth about $60,000. Finally, Van ECK Associates Corp increased its holdings in shares of Dr. Reddy’s Laboratories by 64.3% during the third quarter. Van ECK Associates Corp now owns 823 shares of the company’s stock valued at $64,000 after acquiring an additional 322 shares in the last quarter. Hedge funds and other institutional investors own 3.85% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on RDY. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Nomura downgraded Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. Finally, Barclays lowered their price target on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 6th.

Dr. Reddy’s Laboratories Stock Performance

Shares of RDY stock opened at $14.02 on Friday. The company has a market capitalization of $11.70 billion, a P/E ratio of 22.32 and a beta of 0.50. Dr. Reddy’s Laboratories Limited has a 12-month low of $13.36 and a 12-month high of $16.89. The business’s 50 day moving average is $14.75 and its two-hundred day moving average is $15.32. The company has a current ratio of 1.92, a quick ratio of 1.38 and a debt-to-equity ratio of 0.02.

Dr. Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings data on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.01. Dr. Reddy’s Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Analysts expect that Dr. Reddy’s Laboratories Limited will post 0.8 EPS for the current fiscal year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.